Achieve Life Sciences, Inc.
- Last sale
- Nov 9, 2026 · +1.19%
- Market cap
- $746.48M
- 109.78M shares
- Filings
- 1,034
FY 2019
Q3 2026N/M FY25 yoy
Q3 2012
—Q3 2026derivedN/M FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026+64.1% FY25 yoy
- $746.48M
- —
- —
- 4.1×
- -6.63%
- —
FY2025 figures · derived
Price
Nov 9, 2026 · IEX last sale
IEX last saleClose of recordAs traded
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Financials
Revenue
| Period | Ended | Value | Kind | Source trail |
|---|---|---|---|---|
| FY 2019 | 2019-12-31 | $0 | reported | |
| FY 2018 | 2018-12-31 | $0 | reported |
In vitro & in vivo diagnostic substances
Achieve Life Sciences, Inc. is the 8th largest of the 20 covered companies the SEC files under this code, by total assets. SIC 2835
CompanyRevenueGrowthNet marginAssets
NTLAIntellia Therapeutics, Inc.$67.7M16.9%609.9%$902.6MCLDXCelldex Therapeutics, Inc.$1.5M78.0%16,748.0%$721.5MMYGNMyriad Genetics Inc$824.5M1.6%44.4%$609.2M
ACHVAchieve Life Sciences, Inc. (this company)———$206.4M
TKNOAlpha Teknova, Inc.$40.5M7.4%42.6%$94.7MICCCImmucell Corp$27.6M4.3%3.8%$48.0MNNNNAnbio Biotechnology$8.6M5.6%74.1%$30.2MIMDXInsight Molecular Diagnostics Inc.$4.1M115.6%1,238.5%$21.7MQCLSQ/C Technologies, Inc.———$21.3MPeers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in total assets first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.
Achieve Life Sciences, Inc. · CIK 949858 · Engraved from SEC EDGAR